ARWR

86.64

1.23% 1.05

Handel nachbörslich: 86.70 0.06 +0.07%

Arrowhead Pharmaceuticals Inc (ARWR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ARWR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$85.59

Offen:

$84.75

24-Stunden-Volumen:

817.76K

Relative Volume:

0.39

Marktkapitalisierung:

$12.24B

Einnahmen:

$622.01M

Nettoeinkommen (Verlust:

$-271.86M

KGV:

-40.33

EPS:

-2.1484

Netto-Cashflow:

$-45.87M

1W Leistung:

-1.15%

1M Leistung:

+20.48%

6M Leistung:

+35.76%

1J Leistung:

+361.34%

1-Tages-Spanne:

$83.78

$87.17

1-Wochen-Bereich:

$83.78

$90.97

52-Wochen-Spanne:

$18.73

$95.49

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Firmenname

Arrowhead Pharmaceuticals Inc

Sektor

Healthcare (1080)

Branche

Biotechnology (604)

Telefon

626-696-4702

Adresse

177 E COLORADO BLVD, PASADENA, CA

Mitarbeiter

711

Twitter

@ArrowheadPharma

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

ARWR's Discussions on Twitter

Compare ARWR vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARWR Arrowhead Pharmaceuticals Inc	86.64	12.32B	622.01M	-271.86M	-45.87M	-2.1484
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-21	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-06-05	Eingeleitet	Goldman	Neutral
2023-12-04	Eingeleitet	BofA Securities	Buy
2023-09-19	Eingeleitet	Citigroup	Neutral
2023-07-21	Eingeleitet	TD Cowen	Outperform
2023-05-12	Herabstufung	SVB Securities	Outperform → Market Perform
2023-04-26	Eingeleitet	SMBC Nikko	Outperform
2023-04-12	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2022-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2022-05-11	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-01-19	Fortgesetzt	Goldman	Buy
2021-08-06	Bestätigt	Chardan Capital Markets	Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-02-05	Bestätigt	H.C. Wainwright	Buy
2020-12-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-12-16	Eingeleitet	UBS	Buy
2020-11-19	Eingeleitet	Citigroup	Buy
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-05-08	Hochstufung	Oppenheimer	Perform → Outperform
2020-04-15	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-03-24	Hochstufung	SVB Leerink	Underperform → Mkt Perform
2020-03-17	Eingeleitet	Goldman	Neutral
2020-01-21	Eingeleitet	SVB Leerink	Underperform
2019-12-13	Eingeleitet	Oppenheimer	Perform
2019-11-29	Bestätigt	Chardan Capital Markets	Buy
2019-11-27	Bestätigt	B. Riley FBR	Buy
2019-11-25	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-10-24	Herabstufung	Robert W. Baird	Outperform → Neutral
2019-10-22	Bestätigt	Chardan Capital Markets	Buy
2019-10-03	Eingeleitet	Robert W. Baird	Outperform
2018-09-07	Hochstufung	B. Riley FBR	Neutral → Buy
2018-09-06	Bestätigt	Chardan Capital Markets	Buy
2018-08-08	Bestätigt	Cantor Fitzgerald	Overweight
2018-07-02	Bestätigt	Chardan Capital Markets	Buy

Alle ansehen

Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten

Aug 15, 2026

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Aug 15, 2026

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits

Aug 15, 2026

Aug 14, 2026

Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants - Stock Titan

Aug 14, 2026

Aug 12, 2026

Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight - Sahm

Aug 12, 2026

Aug 11, 2026

Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Aug 11, 2026

Aug 10, 2026

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses - simplywall.st

Aug 10, 2026

FY2026 Earnings Estimate for ARWR Issued By HC Wainwright - MarketBeat

Aug 10, 2026

Zacks Research Analysts Increase Earnings Estimates for ARWR - MarketBeat

Aug 10, 2026

Aug 09, 2026

Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Aug 09, 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 09, 2026

Aug 06, 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - marketbeat.com

Aug 06, 2026

Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120 - Moomoo

Aug 06, 2026

Aug 05, 2026

Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside - TradingView

Aug 05, 2026

Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offering - Endpoints News

Aug 05, 2026